Guanfacine Tablet, Extended Release
Product Images NDC 72162-1798

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 72162-1798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621798)

Label for guanfacine extended-release tablets, USP, showing 1 mg strength. The label indicates a package of 100 tablets with a National Drug Code (NDC) 72162-1798-1. It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Ohm Laboratories Inc. Storage instructions and medication warnings are also displayed.*

FDA Label Image

Spl-fig-1 (Spl Fig 1)

A pharmacokinetic curve comparing Guanfacine extended-release tablets 1 mg QD and Tenex 1 mg QD. The graph shows Guanfacine plasma concentration (ng/mL) on the y-axis and time (hours) on the x-axis, illustrating plasma concentration changes over 24 hours for each formulation.*

FDA Label Image

Spl-fig-2 (Spl Fig 2)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals in Cmax and AUC for Guanfacine when co-administered with CYP3A4 inhibitors (Ketoconazole), CYP3A4 inducers (Rifampin), Oral Methylphenidate, and Lisdexamfetamine Dimesylate. The x-axis shows change relative to reference, with values ranging from 0 to 5.*

FDA Label Image

Spl-fig-3 (Spl Fig 3)

A horizontal error bar chart showing fold change and 90% confidence intervals for Cmax and AUC pharmacokinetic parameters of interacting drugs Oral Methylphenidate and Lisdexamfetamine Dimesylate. The x-axis represents change relative to reference from 0.0 to 2.0, with a vertical line at 1.0 indicating no change.*

FDA Label Image

Spl-fig-4 (Spl Fig 4)

A Kaplan-Meier survival curve chart showing treatment failure percentages over time in days. The chart compares two groups labeled Placebo (solid line) and SPD503 (dashed line), illustrating treatment failure rates increasing over approximately 200 days, with the Placebo group showing higher failure rates than SPD503.*

FDA Label Image

Spl-structure (Spl Structure)

Chemical structure of Guanfacine Hydrochloride, showing a dichlorobenzene ring connected to a guanidine group with an adjacent ketone functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.